RedHill Advances Opaganib as Potential Ebola Treatment Amid Rare Bundibugyo Virus Outbreak
TEL AVIV, Israel and RALEIGH, N.C., June 2, 2026 RedHill Biopharma has announced efforts to advance the clinical development...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TEL AVIV, Israel and RALEIGH, N.C., June 2, 2026 RedHill Biopharma has announced efforts to advance the clinical development...
REHOVOT and RAMAT-GAN, Israel, June 2, 2026 Galmed Pharmaceuticals and Tissue Dynamics have announced a significant preclinical breakthrough in...
SAN FRANCISCO, May 28, 2026 Alife Health has achieved a major milestone in reproductive medicine with the U.S. Food...
SAN DIEGO, June 1, 2026 Ansun Biopharma has announced a significant clinical development milestone after an independent Data Monitoring...
FORT LAUDERDALE, Fla., May 29, 2026 Sunshine Biopharma announced that the United States Patent and Trademark Office has issued...
DURHAM, N.C. and BEIJING, China, May 27, 2026 Brii Biosciences Limited (Brii Bio) has presented new late-breaking clinical and...
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
ORLANDO, Fla., May 19, 2026 Altesa BioSciences announced positive results from its randomized, placebo-controlled Phase 2 rhinovirus challenge study...
BOTHELL, Wash., April 30, 2026 Cocrystal Pharma, Inc., a clinical-stage biotechnology company focused on antiviral therapeutics, has presented new...
